Volume 84 Issue 7 | pp. 58-61
Issue Date: February 13, 2006

Strategies Shift In Contract Biologics

Some fine chemicals makers pull back, while others push ahead on commercial production
Department: Business

When DSM revealed in late December that it was planning to mothball its biologics facility in Montreal and shift its biopharmaceutical focus away from commercial manufacturing "hardware" to technological "software," the announcement had a familiar ring. Dow Chemical's Dowpharma business unit had made a similar move a year earlier, emphasizing development of its Pseudomonas-based Pfenex technology for producing biopharmaceuticals over its previous commercial-scale contract manufacturing plans.

Both companies' decisions were made in the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society